Zasocitinib (TAK-279): A Comprehensive Profile of a Next-Generation Selective TYK2 Inhibitor Poised to Redefine the Oral Treatment Landscape for Immune-Mediated Diseases

Executive Summary

Zasocitinib (TAK-279) is an investigational, orally administered, small-molecule drug that represents a significant advancement in the targeted therapy of immune-mediated inflammatory diseases. It is classified as a next-generation, highly selective, allosteric tyrosine kinase 2 (TYK2) inhibitor. Its molecular design, facilitated by artificial intelligence and computationally enabled strategies, has yielded a compound with unprecedented selectivity for TYK2 over other Janus kinase (JAK) family members, a distinction that underpins its promising clinical profile. The core value proposition of Zasocitinib rests on its ability to deliver efficacy comparable to injectable biologics while maintaining a favorable safety profile devoid of the characteristic adverse events associated with broader JAK inhibition.

Clinical development, spearheaded by Takeda Pharmaceutical following its acquisition from Nimbus Therapeutics, has demonstrated compelling results. In a Phase 2b study in patients with moderate-to-severe plaque psoriasis, Zasocitinib achieved high rates of skin clearance, with one-third of patients on the highest dose attaining complete clearance (PASI 100) at 12 weeks. Similarly, in a Phase 2b study in active psoriatic arthritis, the drug demonstrated statistically significant improvements in joint symptoms (ACR20) and notable efficacy across multiple disease domains, including skin clearance and minimal disease activity. A key pharmacodynamic feature is its ability to provide sustained, 24-hour inhibition of the TYK2 pathway at clinically relevant doses, a stark contrast to the first-in-class competitor, deucravacitinib.

The safety profile observed in these trials has been encouraging, characterized by mostly mild-to-moderate adverse events and, critically, a lack of the hematologic, hepatic, or lipid abnormalities that have prompted regulatory scrutiny of the broader JAK inhibitor class. This clean safety profile suggests the potential for use without the need for routine laboratory monitoring, a significant advantage in clinical practice.

Takeda has positioned Zasocitinib as a cornerstone of its late-stage pipeline, with a comprehensive Phase 3 program underway in psoriasis and psoriatic arthritis, including a pivotal head-to-head superiority trial against deucravacitinib. The company is also exploring its potential in inflammatory bowel disease. With regulatory filings for psoriasis anticipated in fiscal years 2025-2026 and significant peak revenue potential projected, Zasocitinib is poised to not only challenge the existing oral standard of care but also to disrupt the broader market for immune-mediated diseases, offering a compelling new option for patients and clinicians.

Section 1: Foundational Pharmacology and Molecular Design

The unique clinical profile of Zasocitinib is a direct consequence of a deliberate and advanced drug discovery process. Its foundational pharmacology is rooted in a highly specific mechanism of action, enabled by a molecular structure rationally designed for unparalleled selectivity. This section details the chemical identity, mechanism, in vitro potency, and innovative design philosophy that define Zasocitinib as a next-generation therapeutic agent.

1.1 Chemical Identity and Physicochemical Properties

Zasocitinib is a small molecule drug being developed as an oral therapeutic.[1] Its development has been tracked through several identifiers. The generic name is Zasocitinib, while its primary development codes are TAK-279 (used by Takeda) and NDI-034858 (used by its originator, Nimbus Therapeutics).[3]

The compound's precise chemical structure is defined by its International Union of Pure and Applied Chemistry (IUPAC) name: N--7-(methylamino)-5-[(2-oxo-1-pyridin-2-ylpyridin-3-yl)amino]pyrazolo[1,5-a]pyrimidine-3-carboxamide.[3] Its molecular formula is

C23​H24​N8​O3​, and it has a molar mass of 460.498 g/mol.[2] The table below consolidates its key chemical and database identifiers for precise reference.

Identifier Type	Value	Source(s)
Generic Name	Zasocitinib	3
Development Codes	TAK-279, NDI-034858	3
IUPAC Name	N--7-(methylamino)-5-[(2-oxo-1-pyridin-2-ylpyridin-3-yl)amino]pyrazolo[1,5-a]pyrimidine-3-carboxamide	3
CAS Number	2272904-53-5	2
PubChem CID	137441492	3
UNII	C293MNS6TQ	2
ChEMBL ID	ChEMBL5314423	3
KEGG ID	D12941	3
Molecular Formula	C23​H24​N8​O3​	2
Molar Mass	460.498 g·mol⁻¹	2
InChI Key	BWINBHTTZLVXGT-NVXWUHKLSA-N	2

1.2 Mechanism of Action: Allosteric Inhibition of the TYK2 Pseudokinase Domain

Zasocitinib functions as an oral, allosteric inhibitor of Tyrosine Kinase 2 (TYK2).[3] TYK2 is a member of the Janus kinase (JAK) family of non-receptor tyrosine kinases, which are essential intracellular enzymes that transduce signals from cytokine and growth factor receptors on the cell surface.[2] The JAK/STAT signaling pathway is a cornerstone of immune cell function, and its dysregulation is central to the pathogenesis of numerous autoimmune and inflammatory diseases, including psoriasis and psoriatic arthritis.[9]

TYK2, in particular, is a critical signaling partner for key pro-inflammatory cytokines such as interleukin-23 (IL-23), IL-12, and Type I interferons (IFN-α/β).[2] These cytokines are known to be primary drivers of the inflammatory cascade in psoriasis.[9] When these cytokines bind to their receptors, TYK2 is activated and phosphorylates associated STAT (Signal Transducer and Activator of Transcription) proteins. The phosphorylated STATs then dimerize, translocate to the cell nucleus, and bind to DNA to regulate the transcription of genes involved in inflammation, immune response, and cell proliferation.[2]

Unlike traditional orthosteric kinase inhibitors that compete with adenosine triphosphate (ATP) at the enzyme's active catalytic site (the Janus homology 1 or JH1 domain), Zasocitinib employs a more sophisticated allosteric mechanism.[9] It selectively binds to the regulatory pseudokinase domain of TYK2, known as the Janus homology 2 (JH2) domain.[6] The JH2 domain normally functions to control the activity of the adjacent JH1 catalytic domain. By binding to this regulatory site, Zasocitinib stabilizes the JH2 domain in an inhibitory conformation. This prevents the receptor-mediated conformational change that is necessary for the JH1 domain to bind ATP and become active, thereby shutting down the enzyme's kinase activity and blocking all subsequent downstream signaling events.[6] This highly specific mode of action allows for potent inhibition of the IL-23/IL-12/IFN pathways without directly interfering with the catalytic machinery of other closely related kinases.

1.3 The Apex of Selectivity: In Vitro Characterization and Potency

The defining characteristic of Zasocitinib is its extraordinary selectivity for TYK2 over the other three members of the JAK family (JAK1, JAK2, and JAK3). This selectivity has been quantified through rigorous in vitro biochemical and cellular assays, establishing a pharmacological profile that is superior to the first-in-class TYK2 inhibitor, deucravacitinib.

In biochemical binding assays, Zasocitinib binds to the TYK2 JH2 domain with a very high affinity, demonstrated by an inhibitory constant (Ki​) of 0.0087 nM.[10] In contrast, its binding to the JAK1 JH2 domain is exceptionally weak, with a

Ki​ of over 15,000 nM.[13] This represents a selectivity ratio of over 1.7 million-fold in favor of TYK2 over JAK1.[14] This level of selectivity is a profound improvement over deucravacitinib, which has a

Ki​ for the JAK1 JH2 domain of approximately 1 nM, yielding a selectivity ratio of only about 87-fold.[16] This quantitative leap in selectivity is the fundamental basis for Zasocitinib's "next-generation" designation and the scientific rationale for its predicted superior safety profile.

This biochemical selectivity translates directly into functional cellular activity. In human whole-blood assays, which represent a more physiologically relevant system, Zasocitinib potently inhibits TYK2-dependent signaling pathways. The half-maximal inhibitory concentrations (IC50​) for key pathways are:

• IL-23–pSTAT3 pathway: 48.2 nM [10]
• Type I IFN–pSTAT3 pathway: 21.6 nM [10]
• IL-12–pSTAT4 pathway: 57.0 nM [10]

Crucially, even at high concentrations, Zasocitinib demonstrates no measurable inhibition of pathways that are dependent on JAK1, JAK2, or JAK3.[10] This functional selectivity ensures that Zasocitinib's therapeutic effects are precisely targeted to the disease-relevant TYK2 pathways, while sparing the broader physiological functions mediated by other JAKs, such as hematopoiesis (JAK2) and immune surveillance (JAK1/3).

1.4 Innovation in Discovery: The Role of AI-Assisted, Computationally Enabled Design

Zasocitinib's exceptional pharmacological profile was not achieved through traditional trial-and-error screening but is the product of a deliberate, cutting-edge drug design strategy.[8] The discovery process, led by Nimbus Therapeutics, leveraged a computationally enabled platform that included artificial intelligence (AI)-assisted tools and advanced computational physics-based methods like Free Energy Perturbation (FEP+).[11]

This sophisticated approach allowed researchers to screen a vast virtual library of molecular structures and predict their binding affinities with a high degree of accuracy.[11] It facilitated the identification of a novel pyrazolo-pyrimidine core and guided the optimization of the molecule to achieve a perfect "lock-and-key" fit within the allosteric binding pocket of the TYK2 JH2 domain.[11]

The key to its unprecedented selectivity lies in a specific structural feature: a methoxycyclobutyl ring.[12] The computational models predicted, and subsequent structural biology confirmed, that this moiety fits snugly into a pocket on the TYK2 JH2 domain defined by the amino acid residues Val603 and Lys642.[12] However, in the corresponding JH2 domains of JAK1 and JAK2, this pocket is occupied by bulkier isoleucine residues (Ile597 in JAK1 and Ile559 in JAK2).[12] This creates a steric clash, physically preventing the methoxycyclobutyl ring of Zasocitinib from binding effectively to the JAK1 and JAK2 pseudokinase domains.[12]

This rational design process represents a significant evolution in kinase inhibitor discovery. The logical chain of causality is clear: the AI-driven design process enabled the identification of a unique chemical scaffold, the methoxycyclobutyl moiety, which in turn provides a structural basis for perfect binding to the target (TYK2) and steric hindrance at off-target enzymes (JAK1/2). This directly translates into the observed multi-million-fold selectivity, which is the antecedent to the drug's predicted favorable safety profile. Zasocitinib's development serves as a powerful proof-of-concept for how modern computational tools can overcome the historical challenge of achieving high selectivity among closely related enzyme family members, potentially heralding a new era of safer, more precisely targeted small-molecule therapeutics.

Section 2: Clinical Pharmacology: Pharmacokinetics and Pharmacodynamics

The clinical utility of a drug is determined not only by its mechanism of action but also by how it behaves within the human body. The pharmacokinetic (PK) profile of Zasocitinib—its absorption, distribution, metabolism, and excretion—and its pharmacodynamic (PD) effects—the intensity and duration of its biological action—are critical features that underpin its clinical efficacy and dosing regimen. Zasocitinib's clinical pharmacology is distinguished by properties that support convenient once-daily dosing and, most importantly, provide sustained 24-hour engagement of its therapeutic target, a key advantage over its primary competitor.

2.1 Oral Bioavailability and Dosing Profile

Zasocitinib is formulated as an orally active small molecule, intended for administration as a once-daily pill.[3] This oral route offers a substantial advantage in patient convenience, preference, and adherence compared to the injectable biologic therapies that dominate the treatment landscape for moderate-to-severe immune-mediated diseases.[14]

Early-phase clinical studies confirmed that Zasocitinib possesses a pharmacokinetic profile amenable to a simple once-daily dosing schedule.[21] A key contributor to this profile is its extended plasma half-life, which has been reported to be in the range of 16.5 to 30.7 hours.[16] This is significantly longer than the half-life of deucravacitinib, which is approximately 10 hours.[16] The longer half-life of Zasocitinib ensures that therapeutic concentrations are maintained in the bloodstream over a full 24-hour period with a single dose, avoiding the peaks and troughs that can be associated with shorter-acting drugs and potentially leading to more consistent therapeutic effect.

2.2 Sustained Target Engagement: A 24-Hour Pharmacodynamic Advantage

Perhaps the most significant differentiator for Zasocitinib from a clinical pharmacology perspective is its ability to maintain profound and sustained target engagement throughout the entire dosing interval. Pharmacokinetic and pharmacodynamic modeling, based on data from clinical trials, has provided a clear picture of this advantage.

Simulations using a clinically relevant and highly effective dose of 30 mg once daily predict that the plasma concentrations of Zasocitinib remain above the TYK2 IC50​ (the concentration required to inhibit 50% of the enzyme's activity) for the entire 24-hour period.[10] In fact, the concentrations are projected to remain above the

IC90​ threshold for the full 24 hours, indicating strong and continuous target inhibition.[16] This sustained engagement translates into a calculated daily inhibition of TYK2-mediated signaling of approximately 91%.[13]

This profile stands in stark contrast to that of the approved 6 mg once-daily dose of deucravacitinib. Similar modeling for deucravacitinib shows that its plasma concentrations exceed the TYK2 IC50​ for only about 3 hours of the 24-hour dosing interval.[13] This results in a much lower estimated total daily inhibition of only 23-24%.[13] This is not merely a quantitative difference but a qualitative one. The ability of Zasocitinib to continuously suppress the key inflammatory TYK2 pathway throughout the day and night provides a strong scientific rationale for its potential to achieve deeper and more durable clinical responses compared to a drug that provides only intermittent inhibition. It suggests that while both drugs target the same enzyme, Zasocitinib's pharmacological action is far more comprehensive.

Furthermore, even with this sustained high level of TYK2 inhibition, the plasma concentrations of Zasocitinib do not approach the IC50​ required to inhibit JAK1/3-mediated signaling pathways.[13] This reinforces the drug's exceptional selectivity in a dynamic, in vivo clinical setting and supports the hypothesis that maximal therapeutic benefit from TYK2 inhibition can be achieved without incurring the dose-limiting toxicities associated with off-target JAK inhibition.

2.3 Drug-Drug Interaction Potential

To ensure safe and effective use in real-world clinical practice, where patients with chronic inflammatory diseases are often taking multiple medications, a thorough understanding of a drug's potential for drug-drug interactions (DDIs) is essential. Takeda has conducted a dedicated Phase 1 DDI study (NCT06793943) in healthy volunteers to systematically evaluate Zasocitinib's interaction profile.[23]

The study was designed to assess the pharmacokinetic effects of co-administering Zasocitinib with probes for several common interaction pathways:

• A combined oral contraceptive (levonorgestrel/ethinyl estradiol), to assess any impact on hormone metabolism.
• Metformin, a substrate for the MATE (multidrug and toxin extrusion) transporter, to evaluate effects on renal drug transport.
• Digoxin, a substrate for the P-glycoprotein (P-gp) transporter, to evaluate effects on drug efflux pumps.
• Esomeprazole, a proton-pump inhibitor that raises gastric pH, to assess whether Zasocitinib's absorption is pH-dependent.[24]

The primary outcome measures for this study are the standard pharmacokinetic parameters that quantify drug exposure: maximum plasma concentration (Cmax​) and the area under the plasma concentration-time curve (AUCinf​ and AUClast​).[24] While the specific results of this study are not yet publicly available, its execution demonstrates a strategic effort to build a comprehensive data package that supports a simple and predictable dosing regimen. A favorable DDI profile, with minimal interactions, would further enhance Zasocitinib's positioning as a convenient and easy-to-use oral therapy, free from the complex co-medication management required for some other systemic agents.

Section 3: The Clinical Development Trajectory

The journey of Zasocitinib from a promising preclinical compound to a late-stage clinical asset reflects a clear strategic vision and significant corporate investment. Its development path has been shaped by a key acquisition and a subsequent expansion into a broad and ambitious global clinical trial program designed to establish its efficacy and safety across a range of high-need immune-mediated diseases.

3.1 Corporate Development History and Strategic Acquisition

Zasocitinib was discovered and initially developed by Nimbus Therapeutics, a biotechnology company known for its computationally driven drug discovery platform.[1] Under Nimbus's stewardship, the compound was known by the development code NDI-034858 and was advanced through early-phase clinical trials.[1]

In a pivotal strategic move in early 2023, Takeda Pharmaceutical, a global biopharmaceutical company with a strong presence in immunology, acquired the Zasocitinib program from Nimbus.[20] Following the acquisition, the asset was renamed TAK-279 and was integrated into Takeda's late-stage development pipeline.[20] This acquisition was a significant event, representing a multi-billion dollar investment by Takeda and signaling a high degree of confidence in Zasocitinib's potential to become a best-in-class, blockbuster therapy. The acquisition provided Takeda with a high-value asset poised to compete in the lucrative oral inflammatory disease market and leveraged Takeda's global development and commercialization capabilities to accelerate its path to patients.

3.2 Overview of the Global Clinical Trial Program

Since the acquisition, Takeda has initiated a comprehensive and aggressive global clinical development program for Zasocitinib. The program is designed to robustly evaluate its efficacy, safety, and tolerability across multiple indications and patient populations. It spans from completed Phase 1 and Phase 2b studies to a large-scale, ongoing Phase 3 program that will form the basis of regulatory submissions worldwide.[1]

The program's strategy is notably confident, highlighted by the inclusion of a head-to-head superiority study against the current market leader, deucravacitinib. This indicates a strategy aimed not merely at market entry, but at market leadership by directly demonstrating a superior clinical profile. The table below provides a summary of the key clinical trials that constitute the Zasocitinib development program.

Trial Identifier(s)	Phase	Indication(s)	Status	Brief Design	Est. Enrollment	Source(s)
NCT04999839	2b	Plaque Psoriasis	Completed	Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging	259	28
NCT05153148	2b	Psoriatic Arthritis	Completed	Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging	290	30
NCT06973291	3	Plaque Psoriasis	Recruiting	Randomized, Double-Blind, Head-to-Head vs. Deucravacitinib	600	1
NCT06088043	3	Plaque Psoriasis	Active, Not Recruiting	Randomized, Double-Blind, Placebo- and Active-Controlled (Apremilast)	1108	34
NCT06108544	3	Plaque Psoriasis	Active, Not Recruiting	Randomized, Double-Blind, Placebo-Controlled, Withdrawal/Retreatment	N/A	15
NCT06550076	3	Plaque Psoriasis	Recruiting	Open-Label, Long-Term Extension Study	1950	34
NCT06671483	3	Psoriatic Arthritis	Recruiting	Randomized, Double-Blind, Placebo- and Active-Controlled (Biologic-Naïve)	1088	36
NCT06671496	3	Psoriatic Arthritis	Recruiting	Randomized, Double-Blind, Placebo-Controlled (Biologic-Experienced)	600	38
NCT06233461	2b	Crohn's Disease	Recruiting	Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging	268	39
NCT06764615	2	Ulcerative Colitis	Recruiting	Open-Label Extension Study for IBD	N/A	1
NCT07108283	2	Nonsegmental Vitiligo	Not Yet Recruiting	Randomized, Placebo-Controlled, Dose-Ranging	N/A	1

3.3 Therapeutic Indications Under Active Investigation

The clinical program for Zasocitinib is strategically focused on core inflammatory diseases where the TYK2 pathway is well-validated, while also exploring expansion into other areas of unmet need.

• Plaque Psoriasis (PsO): This is the lead indication for Zasocitinib. Following the highly successful Phase 2b trial (NCT04999839), Takeda has launched a robust Phase 3 program designed to confirm these findings and establish superiority over the current standard of oral care.[1] The head-to-head trial against deucravacitinib (NCT06973291) is the centerpiece of this strategy.[1]
• Psoriatic Arthritis (PsA): As a common and debilitating co-morbidity of psoriasis, PsA is the second major pillar of the development program. The positive Phase 2b results (NCT05153148) have led to the initiation of a large Phase 3 program that includes separate studies for patients who are naïve to biologic therapies and for those who have had an inadequate response to them, reflecting a comprehensive approach to this heterogeneous disease.[1]
• Inflammatory Bowel Disease (IBD): Takeda is leveraging its expertise in gastroenterology to explore Zasocitinib's potential in IBD. The IL-23 pathway, which is inhibited by Zasocitinib, is a validated target in IBD. The program includes a Phase 2b dose-ranging study in moderately to severely active Crohn's Disease (NCT06233461) and a Phase 2 study in Ulcerative Colitis (NCT06764615), which, if successful, could significantly expand the drug's commercial potential.[1]
• Other Potential Indications: While the program is broad, Takeda has also made strategic decisions to focus its resources. Development in Systemic Lupus Erythematosus (SLE), another disease with a strong TYK2 rationale, will not be pursued into late-stage trials.[42] Takeda has cited the potential impact of the U.S. Inflation Reduction Act (IRA), which may shorten the period of market exclusivity for small-molecule drugs in certain indications, as a factor in this decision.[43] This likely reflects a pragmatic portfolio prioritization, weighing the high risk and complexity of SLE drug development against the clearer path to success in psoriasis and PsA. Additionally, a Phase 2 trial in nonsegmental vitiligo (NCT07108283) indicates that Takeda is still exploring the drug's utility in other dermatological conditions.[1]

Section 4: Clinical Efficacy in Plaque Psoriasis

The clinical efficacy of Zasocitinib in treating moderate-to-severe plaque psoriasis was rigorously evaluated in a large, multicenter Phase 2b study (NCT04999839). The results from this trial were highly positive, demonstrating not only statistical superiority over placebo but also achieving response rates described as "biologic-level efficacy," setting a high bar for an oral therapy and providing the foundation for the ongoing Phase 3 program.

4.1 Analysis of the Phase 2b Program in Plaque Psoriasis (NCT04999839)

The trial was a randomized, double-blind, placebo-controlled, dose-ranging study conducted across 55 centers in the United States and Canada.[29] A total of 259 adult patients with moderate-to-severe plaque psoriasis (defined as a PASI score

≥ 12, an sPGA score ≥ 3, and body surface area involvement ≥ 10%) were randomized in a 1:1:1:1:1 ratio to receive one of four oral doses of Zasocitinib (2 mg, 5 mg, 15 mg, or 30 mg) or a matching placebo, administered once daily for a 12-week treatment period.[29]

The primary efficacy endpoint was the proportion of patients achieving at least a 75% improvement from baseline in the Psoriasis Area and Severity Index (PASI 75) at Week 12. Secondary endpoints included higher thresholds of skin clearance, such as PASI 90 and PASI 100, as well as the proportion of patients achieving a static Physician's Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear).

The study successfully met its primary endpoint, with the higher doses of Zasocitinib demonstrating a profound and statistically significant improvement in skin clearance compared to placebo. At Week 12, the PASI 75 response rates were significantly higher in the 5 mg (44%), 15 mg (68%), and 30 mg (67%) Zasocitinib groups, compared to just 6% in the placebo group (p<0.001 for all three comparisons).[12] The 2 mg dose group showed an 18% response rate, which was not statistically significant versus placebo.[27]

The efficacy of Zasocitinib was even more pronounced when examining higher bars for clinical response. For PASI 90, which represents near-total skin clearance and is a key secondary endpoint in modern psoriasis trials, the 15 mg and 30 mg doses achieved response rates of 45% and 46%, respectively. This was a dramatic improvement over the placebo group, where 0% of patients achieved a PASI 90 response (p<0.001).[12]

Most impressively, Zasocitinib demonstrated a clear dose-response for achieving complete skin clearance (PASI 100). At the highest dose of 30 mg, a full 33% of patients achieved PASI 100 at Week 12, compared to 0% of patients on placebo (p<0.001).[12] Achieving complete clearance is the ultimate therapeutic goal for patients, and a one-third response rate for an oral agent after only 12 weeks is a powerful demonstration of efficacy that rivals many leading injectable biologics.

These findings were corroborated by the sPGA results. At Week 12, 52% of patients in the 30 mg group achieved an sPGA score of 0 or 1, compared to only 4% in the placebo group (p≤0.001).[27] The data from this trial clearly established a dose-dependent effect, with the 15 mg and 30 mg doses providing robust and clinically meaningful benefits. While efficacy appeared to plateau for the PASI 75 endpoint between the 15 mg and 30 mg doses, the clear superiority of the 30 mg dose in achieving PASI 100 suggests that this higher dose will be critical for maximizing deep responses and will likely be the dose carried forward in pivotal trials aiming to demonstrate superiority over competitors.

The table below summarizes the key efficacy outcomes from this landmark study.

Efficacy Endpoint (at Week 12)	Placebo (n=52)	Zasocitinib 2 mg (n=51)	Zasocitinib 5 mg (n=52)	Zasocitinib 15 mg (n=53)	Zasocitinib 30 mg (n=52)	Source(s)
PASI 75 (% Responders)	6%	18%	44%	68%	67%	27
PASI 90 (% Responders)	0%	8%	21%	45%	46%	12
PASI 100 (% Responders)	0%	N/A	10%	15%	33%	12
sPGA 0/1 (% Responders)	4%	10%	27%	49%	52%	27

Section 5: Clinical Efficacy in Psoriatic Arthritis

Building on the strong rationale for TYK2 inhibition in psoriatic disease, Zasocitinib was also evaluated in a Phase 2b study (NCT05153148) for the treatment of active psoriatic arthritis (PsA). PsA is a complex, heterogeneous inflammatory arthritis that affects joints, entheses, and the skin. The results of this trial demonstrated that Zasocitinib provides significant and clinically meaningful improvements across the core domains of the disease, reinforcing its potential as a comprehensive oral treatment option.

5.1 Analysis of the Phase 2b Program in Psoriatic Arthritis (NCT05153148)

This was a randomized, multicenter, double-blind, placebo-controlled study involving 290 adult patients with active PsA (defined as having symptoms for ≥ 6 months and ≥ 3 tender and ≥ 3 swollen joints).[30] Participants were randomized 1:1:1:1 to receive oral Zasocitinib at doses of 5 mg, 15 mg, or 30 mg, or placebo, once daily for 12 weeks.[30]

The primary endpoint was the proportion of patients achieving an American College of Rheumatology 20 (ACR20) response at Week 12. An ACR20 response represents at least a 20% improvement in tender and swollen joint counts, plus at least a 20% improvement in three of five other domains (e.g., patient pain, patient global assessment, physician global assessment). Secondary endpoints included higher levels of joint response (ACR50 and ACR70), skin clearance (PASI 75), and achievement of Minimal Disease Activity (MDA).

The study successfully met its primary endpoint. At Week 12, the ACR20 response rates were significantly higher in both the 15 mg group (53.3%) and the 30 mg group (54.2%) compared to the placebo group (29.2%) (p=0.002 for both doses).[21] The 5 mg dose group (35.2%) did not achieve a statistically significant separation from placebo.[21]

Consistent efficacy was observed across key secondary endpoints for the higher doses. For the more stringent ACR50 response, 26.7% of patients in the 15 mg group and 26.4% in the 30 mg group were responders, compared to only 9.7% in the placebo group (nominal p≤0.009).[21] Numerically higher rates of ACR70 response were also seen with the 15 mg (14.7%) and 30 mg (13.9%) doses versus placebo (5.6%).[21]

Zasocitinib also demonstrated robust efficacy on the skin manifestations of PsA. Among patients with baseline psoriasis affecting at least 3% of their body surface area, the 30 mg dose led to a PASI 75 response rate of 45.7%, significantly higher than the 15.4% seen with placebo (nominal p=0.002).[21] Skin responses were evident as early as Week 2 of treatment.[31]

A particularly important outcome in modern PsA trials is the achievement of Minimal Disease Activity (MDA). MDA is a stringent composite endpoint reflecting a state of low disease activity across seven domains, including joints, skin, pain, enthesitis, and patient-reported outcomes. Achieving MDA is a key treatment goal. In this study, significantly higher proportions of patients treated with 15 mg (28.0%) and 30 mg (29.2%) of Zasocitinib achieved MDA at Week 12 compared to only 12.5% of patients on placebo (p<0.05).[30] This result is highly compelling as it indicates that Zasocitinib provides holistic control over the multiple facets of PsA, positioning it as a comprehensive therapeutic option rather than one that only addresses joint symptoms.

Importantly, subgroup analyses from the trial showed that the ACR20 response to the 15 mg and 30 mg doses of Zasocitinib was consistent and superior to placebo regardless of patient baseline characteristics, including body weight, sex, or prior exposure to biologic therapies.[45] This suggests that Zasocitinib has the potential for broad applicability across the diverse PsA patient population.

The table below summarizes the key efficacy outcomes from the Phase 2b PsA study.

Efficacy Endpoint (at Week 12)	Placebo (n=72)	Zasocitinib 5 mg (n=71)	Zasocitinib 15 mg (n=75)	Zasocitinib 30 mg (n=72)	Source(s)
ACR20 (% Responders)	29.2%	35.2%	53.3%	54.2%	21
ACR50 (% Responders)	9.7%	N/A	26.7%	26.4%	21
ACR70 (% Responders)	5.6%	N/A	14.7%	13.9%	21
PASI 75 (% Responders)	15.4%	25.6%	28.3%	45.7%	21
MDA (% Responders)	12.5%	N/A	28.0%	29.2%	30

Section 6: Integrated Safety and Tolerability Profile

A cornerstone of the value proposition for Zasocitinib is its potential to offer a superior safety and tolerability profile compared to less selective Janus kinase (JAK) inhibitors. The extensive preclinical characterization predicted that its exquisite selectivity for TYK2 would translate into a clinical safety profile free from the off-target liabilities associated with the inhibition of JAK1, JAK2, and JAK3. The data from the Phase 2b clinical program in both plaque psoriasis and psoriatic arthritis have provided strong clinical validation for this hypothesis.

6.1 Characterization of Treatment-Emergent Adverse Events (TEAEs)

Across the Phase 2b development program, Zasocitinib has been generally well-tolerated.[3] An integrated analysis of the data shows that while the overall frequency of treatment-emergent adverse events (TEAEs) was numerically higher in the Zasocitinib treatment arms compared to placebo, the majority of these events were of mild or moderate severity.[6]

In the psoriasis study, TEAEs occurred in 53-62% of patients across the Zasocitinib dose groups, compared to 44% in the placebo group.[6] In the psoriatic arthritis study, the most commonly reported TEAEs in the combined Zasocitinib groups were nasopharyngitis, upper respiratory tract infections, headache, and rash.[21] Importantly, there was no clear dose-dependent relationship for the incidence of TEAEs, suggesting that the higher, more efficacious doses did not come with a significant tolerability penalty.[8]

The incidence of serious adverse events (SAEs) was low and occurred at a similar frequency in both the Zasocitinib and placebo groups.[21] Crucially, no new or unexpected safety signals were identified during these 12-week studies.[30] Furthermore, there were no reports of opportunistic infections or major adverse cardiovascular events (MACE), which are events of special interest for the broader JAK inhibitor class.[21] This early safety data is consistent with the drug's highly selective mechanism of action.

Common TEAE (PsA Study)	Placebo	Zasocitinib 5 mg	Zasocitinib 15 mg	Zasocitinib 30 mg	Source(s)
Nasopharyngitis	4.2%	8.5%	9.3%	9.7%	21
Upper Respiratory Tract Infection	2.8%	11.3%	4.0%	9.7%	21
Headache	4.2%	2.8%	8.0%	5.6%	21
Rash	0%	4.2%	8.0%	5.6%	21

6.2 Assessment of Laboratory Parameters and Absence of JAK-Related Signals

The most compelling evidence for Zasocitinib's differentiated safety profile comes from the analysis of laboratory monitoring parameters. Broader-acting JAK inhibitors are known to cause dose-dependent changes in various laboratory values due to their inhibition of JAK1, JAK2, and JAK3, which play roles in hematopoiesis and metabolism. These changes can include anemia, neutropenia, lymphopenia, elevations in liver enzymes, and increases in lipid levels, often necessitating routine laboratory monitoring and carrying black box warnings from regulatory agencies.[12]

In stark contrast, the Phase 2b studies of Zasocitinib revealed a lack of clinically meaningful, dose-dependent changes in these laboratory parameters.[12] Longitudinal analysis of hematologic parameters (including neutrophils, lymphocytes, hemoglobin, and platelets), hepatic function tests (ALT and AST), and renal function markers (creatinine) showed that mean values remained within normal ranges throughout the studies and were generally similar to those observed in the placebo groups.[18] No relationship was found between Zasocitinib treatment and the development of cytopenias such as neutropenia or lymphopenia.[46]

This "clean" laboratory profile is the clinical fulfillment of the drug's core design principle. The entire development effort, from the AI-assisted design to the focus on allosteric inhibition of the pseudokinase domain, was aimed at achieving this outcome. The safety data provides the crucial validation that Zasocitinib's exquisite in vitro selectivity translates into a differentiated and safer mechanism of action in patients. This profile not only distinguishes it from pan-JAK inhibitors but also suggests a significant practical advantage: the potential for use without the requirement for routine, burdensome laboratory monitoring.[14] This could fundamentally improve the patient and physician experience, lower barriers to treatment initiation, and reduce the overall cost of care, making Zasocitinib a highly attractive therapeutic option from a clinical workflow perspective.

6.3 Long-Term Safety Evaluation Strategy (NCT06550076)

While the 12-week data from the Phase 2b studies are highly encouraging, confirming the long-term safety and durability of this favorable profile is essential for regulatory approval and widespread clinical adoption. To this end, Takeda has initiated a large, multicenter, open-label extension (OLE) study (NCT06550076).[15]

This study is designed to enroll up to 1950 patients who have successfully completed one of the parent Phase 3 psoriasis trials.[34] Participants will continue to receive Zasocitinib for an extended period of up to 156 additional weeks, or three years.[34] The primary objective of this OLE study is to meticulously collect long-term safety data, with the primary outcome measures being the incidence of TEAEs and SAEs over this prolonged treatment duration.[34]

This study will provide a large and robust dataset on the long-term safety of Zasocitinib, allowing for the detection of any rare or delayed adverse events. The results will be critical for regulatory submissions to agencies like the FDA and EMA and will be instrumental in building the confidence of clinicians and patients in the drug's long-term safety, which is paramount for a therapy intended for chronic use.

Section 7: Strategic Positioning and Competitive Differentiation

Zasocitinib is entering a dynamic and competitive therapeutic landscape for psoriasis and psoriatic arthritis. Its success will depend not only on its absolute efficacy and safety but also on its ability to clearly differentiate itself from existing and emerging competitors. Its strategic positioning is defined by a direct challenge to the first-in-class TYK2 inhibitor, a clear separation from the broader JAK inhibitor class, and the potential to carve out a significant role within established treatment guidelines.

7.1 A Head-to-Head Comparison with Deucravacitinib (Sotyktu)

The most direct and important competitor for Zasocitinib is deucravacitinib (brand name Sotyktu), the first TYK2 inhibitor to be approved for moderate-to-severe plaque psoriasis.[48] A direct comparison reveals key differences that form the basis of Zasocitinib's potential best-in-class profile.

• Mechanism of Action: The fundamental mechanism is identical. Both Zasocitinib and deucravacitinib are oral, allosteric inhibitors that bind to the regulatory JH2 pseudokinase domain of TYK2.[8]
• Molecular Selectivity: This is the primary point of molecular differentiation. As detailed previously, Zasocitinib's AI-enabled design resulted in a selectivity for TYK2 over JAK1 that is orders of magnitude greater than that of deucravacitinib (over 1 million-fold vs. approximately 87-fold).[16] This superior selectivity is hypothesized to translate into a cleaner safety profile with an even lower risk of off-target effects.
• Pharmacodynamics and Target Engagement: This is the most significant clinical pharmacology differentiator. At their respective clinical doses, Zasocitinib (30 mg QD) provides sustained, 24-hour inhibition of the TYK2 pathway, resulting in an estimated 91% total daily inhibition.[13] In contrast, deucravacitinib (6 mg QD) provides only intermittent inhibition, with plasma concentrations exceeding the target threshold for just 3 hours, resulting in an estimated 24% total daily inhibition.[13] This profound difference in target engagement forms a strong hypothesis for potential superiority in clinical efficacy.
• The Clinical Showdown: Recognizing these potential advantages, Takeda has made a bold strategic decision to conduct a Phase 3 head-to-head superiority trial (NCT06973291).[1] This study will directly compare the efficacy, safety, and tolerability of Zasocitinib against deucravacitinib in patients with moderate-to-severe plaque psoriasis. The outcome of this trial will be pivotal. A definitive finding of superiority for Zasocitinib would likely position it to displace deucravacitinib as the standard-of-care oral TYK2 inhibitor and capture the majority of the market for this class.

7.2 Distinguishing from the Pan-JAK Inhibitor Class

While TYK2 is a member of the JAK family, it is crucial to distinguish selective TYK2 inhibitors like Zasocitinib from the broader class of pan-JAK inhibitors (e.g., tofacitinib, baricitinib, upadacitinib).

• Target and Mechanism: Pan-JAK inhibitors are orthosteric inhibitors that bind to the active ATP-binding site (JH1 domain) of multiple JAK enzymes, including JAK1, JAK2, and JAK3.[9] This leads to broad immunosuppression but also to off-target effects related to the inhibition of JAKs involved in other physiological processes. Zasocitinib's allosteric inhibition of only the TYK2 JH2 domain spares the other JAKs entirely.[12]
• Safety Profile: This mechanistic difference is the reason for the distinct safety profiles. The inhibition of JAK1, JAK2, and JAK3 by pan-JAK inhibitors has been associated with an increased risk of serious infections, MACE, malignancies (including lymphoma), and thromboembolic events. These risks have resulted in FDA-mandated black box warnings for the entire class, limiting their use.[12] Zasocitinib's selective profile is specifically designed to avoid these liabilities, and the clinical data to date, showing an absence of these safety signals, supports this differentiation.
• Pharmacodynamic Separation: Comparative modeling highlights this clear separation. While approved JAK inhibitors provide 91-97% daily inhibition of JAK1/3-mediated signaling, Zasocitinib provides 0% inhibition. Conversely, these same JAK inhibitors provide minimal (0-8%) inhibition of TYK2-mediated signaling, while Zasocitinib provides 91%.[13] This demonstrates that they are functionally distinct classes of drugs acting on different pathways.

The table below provides a comparative overview of the key pharmacological features of Zasocitinib, deucravacitinib, and representative pan-JAK inhibitors.

Feature	Zasocitinib	Deucravacitinib	Tofacitinib (Pan-JAK)	Upadacitinib (JAK1-selective)
Primary Target(s)	TYK2	TYK2	JAK1, JAK2, JAK3	JAK1 > JAK2
Mechanism	Allosteric (JH2)	Allosteric (JH2)	Orthosteric (JH1)	Orthosteric (JH1)
Selectivity (TYK2 vs JAK1)	>1,000,000-fold	~87-fold	N/A (inhibits both)	N/A (inhibits both)
Est. % Daily TYK2 Inhibition	91%	23-24%	Minimal (0-8%)	Minimal (0-8%)
Est. % Daily JAK1/3 Inhibition	0%	3%	91-97%	91-97%
Dosing	Once Daily	Once Daily	Twice Daily	Once Daily
Black Box Warning	No (Investigational)	No	Yes	Yes

7.3 Potential Placement within Current Psoriasis and PsA Treatment Guidelines

The treatment of psoriasis and psoriatic arthritis follows a stepwise approach outlined in guidelines from major professional bodies like the American College of Rheumatology (ACR), National Psoriasis Foundation (NPF), European Alliance of Associations for Rheumatology (EULAR), and the American Academy of Dermatology (AAD).[50]

For moderate-to-severe disease, after failure of topical therapies, patients are typically candidates for systemic therapy. This includes conventional oral systemic drugs (e.g., methotrexate, apremilast), injectable biologics (targeting TNF, IL-17, or IL-23), and targeted oral therapies like JAK inhibitors.[50]

Deucravacitinib has successfully carved out a niche as a preferred first-line oral option for many patients who are candidates for systemic therapy, offering efficacy superior to apremilast with a more favorable safety profile than pan-JAK inhibitors.[48]

Zasocitinib is positioned to directly compete for and potentially dominate this space. If the Phase 3 head-to-head trial demonstrates superiority over deucravacitinib, Zasocitinib could become the new standard of care for oral treatment in systemic-naïve patients. Furthermore, its "biologic-level efficacy," particularly the high rates of complete skin clearance (PASI 100), combined with the convenience of an oral pill and a clean safety profile, could position it as a compelling alternative to injectable biologics. This could allow it to be used earlier in the treatment paradigm and also as an effective option for patients who have had an inadequate response to or are hesitant to start injectable therapies. Its success could exert significant competitive pressure on the multi-billion dollar biologics market by offering a less burdensome yet highly effective treatment modality.

Section 8: Regulatory and Commercial Outlook

With a robust clinical data package emerging and a comprehensive late-stage development program underway, Zasocitinib is advancing steadily toward regulatory review and commercial launch. Its outlook is shaped by clear regulatory milestones, its strategic importance within Takeda's pipeline, and the pivotal clinical questions that will be answered in the near future.

8.1 Global Regulatory Status and Anticipated Milestones

Zasocitinib remains an investigational drug and has not yet received marketing authorization from any regulatory agency. However, its path to submission is becoming increasingly clear.

• U.S. Food and Drug Administration (FDA): Takeda has provided clear guidance on its submission timelines. The company is on track to submit regulatory filings for the plaque psoriasis indication to the FDA during the fiscal years 2025-2026.[57] This timeline is contingent on the successful completion and positive results of the ongoing Phase 3 program. A subsequent filing for the psoriatic arthritis indication is anticipated in fiscal years 2027 through 2029.[57]
• European Medicines Agency (EMA): The regulatory process in the European Union is also actively progressing. A critical and mandatory step for any new drug seeking approval in the EU is the agreement of a Paediatric Investigation Plan (PIP) with the EMA's Paediatric Committee (PDCO). On May 15, 2024, the EMA issued a decision agreeing to the PIP for Zasocitinib for the treatment of psoriasis.[58] This plan outlines the required studies to ensure the medicine is appropriately evaluated for use in children. The agreed PIP includes a waiver for children from birth to less than 6 years of age and a deferral for the completion of pediatric studies until after studies in adults are completed.[59] The formal agreement on a PIP is a significant milestone, as it confirms a viable regulatory path forward in Europe and represents an early, indirect signal of confidence from regulators in the overall development program. Takeda's Phase 3 trials are actively enrolling patients in multiple EU member states, with an estimated global completion date for the PsA program in mid-2028.[60]

8.2 Zasocitinib as a Pillar of Takeda's Late-Stage Pipeline

Takeda's leadership has publicly and repeatedly emphasized the strategic importance of Zasocitinib to the company's future growth. It is not considered a niche asset but a central pillar of its late-stage R&D pipeline.

At investor and R&D-focused events, Takeda has highlighted Zasocitinib as one of six key late-stage programs that are poised to deliver the company's next wave of innovative medicines and drive sustainable long-term growth.[57] The company has attached significant commercial expectations to this basket of assets, projecting a combined peak revenue potential of $10-20 billion.[57] While this figure is not specific to Zasocitinib alone and is not adjusted for the probability of success, its inclusion in this high-value group underscores the blockbuster potential that Takeda foresees for the drug.

The next major catalyst for the program will be the data readouts from the pivotal Phase 3 psoriasis studies, which are expected in 2025.[57] These results will be instrumental in confirming the Phase 2b findings and will form the core of the upcoming regulatory submissions.

8.3 Future Directions and Unanswered Questions

Despite the strong momentum and promising data, several critical questions remain that will define the ultimate success and full potential of Zasocitinib.

• The Head-to-Head Outcome: The single most important unanswered question is the result of the Phase 3 superiority trial (NCT06973291) against deucravacitinib. A definitive win in this trial would solidify Zasocitinib's claim as the best-in-class TYK2 inhibitor and would be a powerful tool for driving market adoption and securing favorable formulary access. A non-superiority finding would necessitate a more nuanced competitive strategy.
• Expansion into Inflammatory Bowel Disease: The ongoing Phase 2 trials in Crohn's disease and ulcerative colitis represent the most significant opportunity for pipeline expansion. The TYK2/IL-23 pathway is a validated target in IBD, but the efficacy of Zasocitinib in this setting is not yet known. Positive data from these studies would dramatically increase the drug's overall peak revenue potential and establish its utility beyond dermatology and rheumatology.
• Confirmation of Long-Term Safety: While the short-term safety profile is excellent, the long-term data from the open-label extension study (NCT06550076) will be essential. Confirming the durable safety of Zasocitinib over several years of continuous use is the final step in cementing its differentiation from the pan-JAK inhibitor class and providing ultimate reassurance to prescribers and patients.
• Real-World Performance: Beyond the controlled environment of clinical trials, key questions remain about how Zasocitinib's superior PK/PD profile and high efficacy will translate to real-world effectiveness, patient adherence, and the durability of response over many years of treatment. These questions can only be fully answered following its potential launch and widespread clinical use.

Conclusion and Expert Recommendations

Zasocitinib (TAK-279) has emerged as a highly promising, scientifically robust, and rationally designed therapeutic agent. It represents a true "next-generation" TYK2 inhibitor, distinguished by a molecular design that confers unprecedented selectivity and a pharmacokinetic profile that enables sustained, 24-hour target engagement. The clinical data from Phase 2b studies in both plaque psoriasis and psoriatic arthritis are compelling, demonstrating the achievement of "biologic-level efficacy" with an oral, once-daily pill.

The combination of this high efficacy with a safety and tolerability profile that appears to be free from the characteristic liabilities of the broader JAK inhibitor class positions Zasocitinib as a potentially transformative treatment option. It has the potential to become a best-in-class oral therapy, offering a new standard of care for patients with moderate-to-severe immune-mediated inflammatory diseases.

Based on this comprehensive analysis, the following expert recommendations are provided for stakeholders monitoring the asset's development:

• Primary Focus on the Head-to-Head Trial: The outcome of the Phase 3 superiority trial (NCT06973291) versus deucravacitinib is the most critical near-term catalyst and will be the primary determinant of Zasocitinib's commercial trajectory. A finding of statistical superiority in efficacy and/or safety would provide a clear path to market leadership within the TYK2 inhibitor class.
• Monitor Long-Term Safety Data Closely: The long-term safety profile is the lynchpin of Zasocitinib's differentiation strategy. Stakeholders should closely monitor emerging data from the open-label extension study (NCT06550076) to confirm the durability of the favorable safety profile observed in shorter-term trials. The absence of any emergent JAK-related safety signals over multi-year exposure will be crucial for maximizing physician confidence and patient uptake.
• Evaluate the IBD Program as the Key Growth Driver: The ongoing Phase 2 studies in Crohn's disease and ulcerative colitis represent the most significant opportunity for value expansion beyond the initial indications. Positive proof-of-concept data in IBD would substantially increase the asset's overall peak revenue potential and solidify its position as a franchise-level product for Takeda. The results of these trials should be considered a major inflection point for the program's long-term valuation.

Works cited

1. Zasocitinib - Drug Targets, Indications, Patents - Patsnap Synapse, accessed August 21, 2025, https://synapse.patsnap.com/drug/8ff8342c27514cddae83150ecbba62c8
2. Zasocitinib: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed August 21, 2025, https://go.drugbank.com/drugs/DB19278
3. Zasocitinib - Wikipedia, accessed August 21, 2025, https://en.wikipedia.org/wiki/Zasocitinib
4. Zasocitinib | 99.91%(HPLC) | In Stock | JAK inhibitor - Selleck Chemicals, accessed August 21, 2025, https://www.selleckchem.com/products/zasocitinib.html
5. Zasocitinib - Takeda - AdisInsight - Springer, accessed August 21, 2025, https://adisinsight.springer.com/drugs/800060068
6. Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial - PubMed Central, accessed August 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11339701/
7. pmc.ncbi.nlm.nih.gov, accessed August 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11339701/#:~:text=Zasocitinib%20(formerly%20TAK%2D279),and%20subsequent%20downstream%20signaling%20events.
8. AAD Reading Room | Zasocitinib Showed Efficacy and Safety After Phase 2 RCT, accessed August 21, 2025, https://www.medpagetoday.com/reading-room/aad/psoriasis/113049
9. Targeted therapy for psoriasis: A focus on tyrosine kinase 2 inhibitors - PsOPsA Hub, accessed August 21, 2025, https://psoriasis-hub.com/medical-information/targeted-therapy-for-psoriasis-a-focus-on-tyrosine-kinase-2-inhibitors
10. Pharmacological Characterization of Zasocitinib (TAK-279): An Oral ..., accessed August 21, 2025, https://pubmed.ncbi.nlm.nih.gov/40441292/
11. Discovery of a Potent and Selective Tyrosine Kinase 2 Inhibitor: TAK-279 | Journal of Medicinal Chemistry - ACS Publications, accessed August 21, 2025, https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.3c00600
12. TKY2 Inhibitor Zasocitinib Shows Promise as Psoriasis Drug - BreakingMED, accessed August 21, 2025, https://breakingmed.org/article.html?articleid=89472
13. P110 Zasocitinib (TAK-279) exhibits high levels of TYK2 inhibition and no inhibition of JAK 1/3 when compared with licensed TYK2 and JAK inhibitors | British Journal of Dermatology | Oxford Academic, accessed August 21, 2025, https://academic.oup.com/bjd/article/191/Supplement_3/ljae360.140/7916099
14. AI-Powered Innovation: Zasocitinib's Journey to Precision Inhibition - Dermatology Times, accessed August 21, 2025, https://www.dermatologytimes.com/view/ai-powered-innovation-zasocitinib-s-journey-to-precision-inhibition
15. Zasocitinib: AI-Designed TYK2 Inhibitor Shows Promise in Psoriasis and Psoriatic Arthritis Treatment - MedPath, accessed August 21, 2025, https://trial.medpath.com/news/46255192148953e1/ai-powered-innovation-zasocitinib-s-journey-to-precision-inhibition-dermatology-times
16. Targeted TYK2 Blockade for PsO Without JAK1/2/3 Impact - Dermatology Times, accessed August 21, 2025, https://www.dermatologytimes.com/view/targeted-tyk2-blockade-for-pso-without-jak1-2-3-impact
17. 'Next-Generation TYK2 Inhibitor': Insights into Zasocitinib - Dermatology Times, accessed August 21, 2025, https://www.dermatologytimes.com/view/-next-generation-tyk2-inhibitor-insights-into-zasocitinib
18. Novel TYK2 inhibitor Zasocitinib | RheumNow, accessed August 21, 2025, https://rheumnow.com/news/novel-tyk2-inhibitor-zasocitinib
19. Zasocitinib shows promise in psoriatic arthritis phase 2b trial - Dermatology Republic, accessed August 21, 2025, https://www.dermatologyrepublic.com.au/zasocitinib-shows-promise-in-psoriatic-arthritis-phase-2b-trial/3854
20. Takeda's oral TYK2 inhibitor matches biologic efficacy - Drug Discovery and Development, accessed August 21, 2025, https://www.drugdiscoverytrends.com/tak-279-an-oral-small-molecule-tyk2-inhibitor-offering-the-convenience-of-a-once-daily-pill-and-biologic-like-clinical-responses/
21. Takeda Phase 2b TAK-279 data in psoriatic arthritis ACR Convergence, accessed August 21, 2025, https://www.takeda.com/newsroom/newsreleases/2023/takeda-phase-2b-tak-279-data-in-psoriatic-arthritis-acr-convergence/
22. Zasocitinib (TAK-279) Displays High Levels of TYK2 Inhibition and No Inhibition of JAK 1/3 Compared with Licensed TYK2 and JAK Inhibitors - ACR Meeting Abstracts, accessed August 21, 2025, https://acrabstracts.org/abstract/zasocitinib-tak-279-displays-high-levels-of-tyk2-inhibition-and-no-inhibition-of-jak-1-3-compared-with-licensed-tyk2-and-jak-inhibitors/
23. zasocitinib (TAK-279) / Takeda, Schrodinger - LARVOL DELTA, accessed August 21, 2025, https://delta.larvol.com/Products/?ProductId=2e37a969-366e-4ae2-8cb1-47ec1e38b57d
24. A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults, accessed August 21, 2025, https://clinicaltrials.takeda.com/study-detail/b330809145414f2b?
25. A Study of Interaction of Zasocitinib (TAK-279) With Other Medicines in Healthy Adults | Clinical Research Trial Listing - CenterWatch, accessed August 21, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT06793943/a-study-of-interaction-of-zasocitinib-tak-279-with-other-medicines-in-healthy-adults
26. Ejim Mark, MD, MPH: Zasocitinib Shows Promise as Next-Generation TYK2 Inhibitor for PsA, accessed August 21, 2025, https://www.hcplive.com/view/ejim-mark-md-mph-zasocitinib-shows-promise-as-next-generation-tyk2-inhibitor-for-psa
27. Takeda Announces Positive Results in Phase 2b Study of ..., accessed August 21, 2025, https://www.takeda.com/newsroom/newsreleases/2023/takeda-announces-positive-results-in-phase-2b-study-of-investigational-tak-279/
28. FC24 Zasocitinib (TAK-279), an oral, allosteric, highly selective TYK2 inhibitor, modulates disease-central cytokine pathways that define clinical response in patients with moderate-to-severe plaque psoriasis - Oxford Academic, accessed August 21, 2025, https://academic.oup.com/bjd/article/191/Supplement_3/ljae360.024/7916093
29. Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial - PubMed, accessed August 21, 2025, https://pubmed.ncbi.nlm.nih.gov/39167366/
30. Highly selective tyrosine kinase 2 inhibition with zasocitinib (TAK-279) improves outcomes in patients with active psoriatic arthritis: a randomised phase 2b study - PubMed, accessed August 21, 2025, https://pubmed.ncbi.nlm.nih.gov/40615297/
31. Zasocitinib (TAK-279), a Highly Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, Elicits Early Skin Responses and Minimal Disease Activity in Patients with Active Psoriatic Arthritis: Results from a Randomized Phase 2b Study - ACR abstract, accessed August 21, 2025, https://acrabstracts.org/abstract/zasocitinib-tak-279-a-highly-selective-oral-tyrosine-kinase-2-tyk2-inhibitor-elicits-early-skin-responses-and-minimal-disease-activity-in-patients-with-active-psoriatic-arthritis-results-from-a/
32. A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis | ClinicalTrials.gov, accessed August 21, 2025, https://clinicaltrials.gov/study/NCT06973291
33. A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis - Takeda Clinical Trials, accessed August 21, 2025, https://clinicaltrials.takeda.com/study-detail/d7637ec263d7454e?
34. A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis, accessed August 21, 2025, https://www.clinicaltrials.gov/study/NCT06550076
35. A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period - Takeda Clinical Trials, accessed August 21, 2025, https://clinicaltrials.takeda.com/study-detail/516bd1c8c4dd4621
36. A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines | ClinicalTrials.gov, accessed August 21, 2025, https://clinicaltrials.gov/study/NCT06671483
37. TAK-279-PsA-3001 | Clinical Trial Summary, accessed August 21, 2025, https://clinicaltrials.takeda.com/study-detail/175345f32479452b
38. A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines, accessed August 21, 2025, https://clinicaltrials.takeda.com/study-detail/2caa81a7bad14915
39. A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease | ClinicalTrials.gov, accessed August 21, 2025, https://clinicaltrials.gov/study/NCT06233461
40. Oral Zasocitinib Demonstrates Safety and Efficacy in Moderate to Severe Plaque Psoriasis, accessed August 21, 2025, https://www.dermatologytimes.com/view/oral-zasocitinib-demonstrates-safety-and-efficacy-in-moderate-to-severe-plaque-psoriasis
41. Zasocitinib Data Demonstrates Efficacy of TYK2 Inhibition for ..., accessed August 21, 2025, http://www.hcplive.com/view/zasocitinib-data-demonstrates-efficacy-of-tyk2-inhibition-for-psoriatic-arthritis
42. Zasocitinib by Takeda Pharmaceutical for Ulcerative Colitis: Likelihood of Approval, accessed August 21, 2025, https://www.pharmaceutical-technology.com/data-insights/zasocitinib-takeda-pharmaceutical-ulcerative-colitis-likelihood-of-approval/
43. R&D In The IRA Era: Takeda Opts Not To Develop Zasocitinib For Lupus, accessed August 21, 2025, https://insights.citeline.com/scrip/leadership/interviews/rd-in-the-ira-era-takeda-opts-not-to-develop-zasocitinib-for-lupus-ZJJ4UE4H7ZD65IOVI6XOS3I4YU/
44. Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial - Health Sciences Research Commons - The George Washington University, accessed August 21, 2025, https://hsrc.himmelfarb.gwu.edu/gwhpubs/5932/
45. Influence of Patient Baseline Characteristics on Zasocitinib (TAK-279) Efficacy, a Selective Oral Tyrosine Kinase 2 Inhibitor: A Randomized Phase 2b Trial in Psoriatic Arthritis - ACR Meeting Abstracts, accessed August 21, 2025, https://acrabstracts.org/abstract/influence-of-patient-baseline-characteristics-on-zasocitinib-tak-279-efficacy-a-selective-oral-tyrosine-kinase-2-inhibitor-a-randomized-phase-2b-trial-in-psoriatic-arthritis/
46. Evaluation of Changes in Laboratory Parameters from a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Selective TYK2 Inhibitor, in Patients with Moderate-to-Severe Plaque Psoriasis | SKIN The Journal of Cutaneous Medicine, accessed August 21, 2025, https://skin.dermsquared.com/skin/article/view/3141?articlesBySameAuthorPage=8
47. Evaluation of Changes in Laboratory Parameters from a Phase 2b Trial of Zasocitinib (TAK-279), an Oral, Selective TYK2 Inhibitor, in Patients with Moderate-to-Severe Plaque Psoriasis - ResearchGate, accessed August 21, 2025, https://www.researchgate.net/publication/385908807_Evaluation_of_Changes_in_Laboratory_Parameters_from_a_Phase_2b_Trial_of_Zasocitinib_TAK-279_an_Oral_Selective_TYK2_Inhibitor_in_Patients_with_Moderate-to-Severe_Plaque_Psoriasis
48. FDA Approves Sotyktu™ for Psoriasis, accessed August 21, 2025, https://www.psoriasis.org/advance/fda-approves-sotyktu-for-psoriasis/
49. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors - PMC - PubMed Central, accessed August 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8484413/
50. Psoriatic arthritis - Diagnosis & treatment - Mayo Clinic, accessed August 21, 2025, https://www.mayoclinic.org/diseases-conditions/psoriatic-arthritis/diagnosis-treatment/drc-20354081
51. Psoriatic Arthritis Guidelines - The National Psoriasis Foundation, accessed August 21, 2025, https://www.psoriasis.org/psa-guidelines/
52. Psoriasis clinical guideline - American Academy of Dermatology, accessed August 21, 2025, https://www.aad.org/member/clinical-quality/guidelines/psoriasis
53. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update | Annals of the Rheumatic Diseases, accessed August 21, 2025, https://ard.bmj.com/content/83/6/706
54. Treatment Guidelines for Psoriatic Arthritis, accessed August 21, 2025, https://www.arthritis.org/health-wellness/treatment/treatment-plan/you-your-doctor/treatment-guidelines-for-psoriatic-arthritis-arthr
55. Treatment Guidelines - The National Psoriasis Foundation, accessed August 21, 2025, https://www.psoriasis.org/treatment-guidelines/
56. Sotyktu | European Medicines Agency (EMA), accessed August 21, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/sotyktu
57. Takeda Advances High-Value Late-Stage Pipeline for Growth, accessed August 21, 2025, https://www.takeda.com/newsroom/newsreleases/2024/takeda-late-stage-pipeline-2024/
58. EMEA-003478-PIP01-23 - paediatric investigation plan | European Medicines Agency (EMA), accessed August 21, 2025, https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003478-pip01-23
59. European Medicines Agency decision P/0182/2024 of 15 May 2024 on the agreement of a paediatric investigation plan and on the gra, accessed August 21, 2025, https://www.ema.europa.eu/en/documents/pip-decision/p-0182-2024-ema-decision-15-may-2024-agreement-paediatric-investigation-plan-granting-deferral-granting-waiver-zasocitinib-emea-003478-pip01-23_en.pdf
60. A Study of Zasocitinib in Adults with Psoriatic Arthritis Who Have Not Taken Biologic Medicines - Clinical Trials in the European Union - EMA, accessed August 21, 2025, https://euclinicaltrials.eu/ctis-public/view/2024-513111-27-00?lang=en
61. Takeda Highlights Value Of Late-Stage Pipeline - Citeline News & Insights, accessed August 21, 2025, https://insights.citeline.com/scrip/r-and-d/takeda-highlights-value-of-late-stage-pipeline-7C6FFAXPKBDKRHXOOVJ54PEWDA/